ArticleIranian journal of basic medical sciences2026
Huanglian Jiedu decoction ameliorates Alzheimer's disease by regulating calcium homeostasis via mitochondria-associated endoplasmic reticulum membranes.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Huanglian Jiedu decoction (HLJDD), a classic traditional Chinese medicine formula, is investigated for its protective effects against Alzheimer's disease (AD). This study explored its mechanism in an AD cell model, focusing on calcium ion (Ca²⁺) homeostasis regulation via mitochondria-associated endoplasmic reticulum membranes (MAMs). Materials and Methods: Mouse hippocampal HT22 cells were induced with 10 μmol·L⁻¹ Aβ₁₋₄₂ to establish the AD model, then divided into blank, model, and 15% HLJDD-containing serum intervention groups. Fluorescent dyes, qRT-PCR, western blotting, laser scanning confocal microscopy, and Annexin V-FITC/PI staining were used to detect intracellular reactive oxygen species (ROS), mitochondrial membrane potential, VDAC1/GRP75/IP3R (mRNA/protein levels), MAMs formation, intracellular Ca²⁺, and cell apoptosis, respectively. Results: Aβ₁₋₄₂ reduced HT22 viability in a concentration-dependent manner, while HLJDD significantly improved viability. Compared to the model group, HLJDD evidently decreased ROS levels ( Conclusion: HLJDD exerts protective anti-AD effects likely by reducing MAMs formation to alleviate intracellular Ca²⁺ overload, thereby lessening cell damage and apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.